PLXProtalix BioTherapeuticsPLX info
$1.09info-0.91%24h
Global rank22521
Market cap$79.52M
Change 7d-
YTD Performance-38.76%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Protalix BioTherapeutics (PLX) Stock Overview

    Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

    PLX Stock Information

    Symbol
    PLX
    Address
    2 University PlazaHackensack, NJ 07601United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.protalix.com
    Country
    🇺🇸 United States
    Phone Number
    201 696 9345

    Protalix BioTherapeutics (PLX) Price Chart

    -
    Value:-

    Protalix BioTherapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.09
    N/A
    Market Cap
    $79.52M
    N/A
    Shares Outstanding
    72.95M
    N/A
    Employees
    193.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org